KEQU Institutional Ownership

KEWAUNEE SCIENTIFIC CORP /DE/

Latest close $37.08 as of Aug 7, 2026

KEQU institutional ownership at a glance

Follow KEWAUNEE SCIENTIFIC CORP /DE/ institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.

Latest filing: Northern Trust filed Schedule 13G amendment on Feb 17, 2026, reporting 252.3K shares and 12.00% beneficial ownership.

Browse recent ownership filings How Schedule 13G works Why a 13G is not a trade report

How to read Schedule 13 ownership changes

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.

Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.

Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

This gauge summarizes recent agreement across tracked institutional activity.

Latest filing Feb 17, 2026

Public consensus preview Reduction leaning 37/100 institutional research score

1 tracked institution Latest filing Feb 17, 2026

1 reducing across 1 comparable institution.

Accumulating0

Unchanged0

Reducing1

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$30.33 52-week high$71.33

Latest close $37.08 16.5% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Dec 31, 2025

Northern Trust Feb 17, 2026 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists, portfolio tools, and the first live gauge on the default tracker. Investor or Pro reveals research gauges across tracker views and unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 4 filing(s) · 1 older require more history access

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
Northern Trust CIK0000073124	Dec 31, 2025 observed Feb 17, 2026 filed · 48d Schedule 13G amendment	Reported reduction	252.3K -49.4K	12.00% 0.00 pts	$37.41	$40.00	$37.08
Northern Trust CIK0000073124	Dec 31, 2023 observed Feb 13, 2024 filed · 44d Schedule 13G amendment	Reported reduction	301.8K -7.3K	12.00% 0.00 pts	$29.07	$29.01	$37.08
Northern Trust CIK0000073124	Dec 31, 2022 observed Feb 13, 2023 filed · 44d Schedule 13G amendment	Reported reduction	309.1K -12.8K	12.00% 0.00 pts	$15.95	$15.60	$37.08

Explore more institutional activity

Related research

Compare KEQU with other securities showing similar institutional activity or recent accumulation across several tracked institutions.

Similar institutional activity

VERA VERA THERAPEUTICS INC 37/100 Reduction leaning NOKBF NOKIA OYJ 37/100 Reduction leaning REZI RESIDEO TECHNOLOGIES, INC. 37/100 Reduction leaning VTRS Viatris Inc 37/100 Reduction leaning

Recent multi-institution accumulation

OCGN OCUGEN INC 2 accumulating Aug 7, 2026 DNTH Dianthus Therapeutics, Inc. /DE/ 2 accumulating Aug 7, 2026 SRPT Sarepta Therapeutics, Inc. 2 accumulating Aug 7, 2026 RARE ULTRAGENYX PHARMACEUTICAL IN 2 accumulating Aug 7, 2026